NeoGenomics, Inc. (OTC BB: NGNM) is known as the only publicly-traded pure-play laboratory testing service provider that has a specific focus on high revenue cancer genetics testing. The combination of advances in technology and genetic research, with the complete sequencing of the human genome, sophisticated new scientific testing tools to diagnose and treat diseases have been made possible. The company’s two facilities in Ft. Myers, Fla., and other facilities in Nashville, Tenn. and Irvine, Calif provide state of the art genetic testing. For further information, visit the Company’s web site at www.neogenomics.org.
- 17 years ago
QualityStocks
NeoGenomics, Inc. (OTC BB: NGNM)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) Reports Q3 2025 Net Income of $1.5 Million and 42% Gross Margin, Highlighting Strong Operational Turnaround
Massimo Group (NASDAQ: MAMO), a provider of powersports vehicles and related equipment, reported revenue of…
-
QualityStocksNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Completes Montauban Mill Building, Moves Toward Commissioning and First Gold-Silver Production in 2026
This article has been disseminated on behalf of ESGold Corp. and may include paid advertising. ESGold…
-
QualityStocksNewsBreaks – D-Wave (NYSE: QBTS) Advantage2TM Quantum Computer Now Available for U.S. Government Applications at Davidson Technologies
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a global leader in quantum computing systems, software and…